LOS ANGELES, CA / ACCESSWIRE / June 20, 2019 / Compare-autoinsurance.org has launched a new blog post that explains how car insurance quotes can help drivers save money.

For more info and free car insurance quotes, visit https://compare-autoinsurance.org/save-money-with-car-insurance-quotes-online/

Policyholders can use online car insurance quotes to save insurance money. Car insurance can be costly, but it could be costlier for drivers to not have one. The penalties for driving without insurance can be severe and they range from fines to jail time. Besides that, uninsured drivers that cause accidents and can’t pay for the damages they have done will probably lose some of their assets in order to pay the victims.

Drivers should understand how policies work and how much coverage they need. In order to get online insurance quotes, drivers can search them on insurance companies’ websites or specialized brokerage websites.

People that scan the insurance market will find out more relevant info about their insurance company competitors and if they offer better insurance deals. More and more insurance companies, encourage the usage of online quotes in order to save money.

Some insurers provide a series of discounts for those that get online quotes. The discounts range from 5% to 10%. For high-risk drivers, getting quotes from non-standard carriers is very important. By doing so, high-risk drivers can get the best insurance plan in order to drive legally.

For additional info, money-saving tips and free car insurance quotes, visit https://compare-autoinsurance.org/

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

“Drivers can save lots of money if they obtain and compare a sufficient number of online quotes before they sign any insurance contract,” said Russell Rabichev, Marketing Director of Internet Marketing Company.

Contact: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Company

ReleaseID: 549335

SAN FRANCISCO, CA and HORSHAM, ENGLAND / ACCESSWIRE / June 20, 2019 / endpoint Clinical, the leading global interactive response technology (IRT®) company, and Cmed Technology, the technology division of a full-service CRO with its encapsia clinical data suite, announced today a new interoperability in their clinical trial software systems. This revolutionary integration allows the power of IRT to be accessed through eSource, reducing site burden, the number of software systems used and operational study costs.

“With both organizations focused on simplifying the management of complex trials, particularly oncology studies, it was a natural partnership to integrate our two state-of-the-art technology systems to provide sites with a more advanced and modern-day approach to clinical trial management,” says Vincent Puglia, Senior Director, Strategic Alliances, endpoint.

The new technology offering was designed by connecting endpoint’s leading-edge technology platforms, PULSE and DRIVE, with Cmed’s new dedicated web app, Inventory, further increasing the scope of its third generation clinical data suite encapsia.

“Although clinical trial designs become more complex over time, it shouldn’t mean that they get more challenging to manage. We need to provide all sites with technology that is intuitive and easy to use. With encapsia, site users no longer have the burden of using a separate IRT system. The most complex IRT tasks handled by endpoint’s IRT platform, like managing subject data as well as randomization, inventory management and drug dispensation can now be performed in real time using the single interface and unified database of encapsia. This revolutionary advancement not only benefits sites by saving them time and burden but also time and cost savings that carry through to the entire clinical study,” says Timothy Corbett-Clark, CTO, Cmed.

Site users see immediate benefits through this advanced technology by being able to perform all the tasks of an eCRF and IRT within the single user interface of encapsia, including:

An intuitive “barcode first” approach to process and inventory shipments quickly;
The ability to record and validate patient data, request drug dispensation, perform drug accountability, or randomize directly from the eSource iPad app. IRT data is automatically populated into encapsia, making the patient visit smooth and quick;
Trial specific nuances are easily accommodated through configurable dispensation workflows;
Inbuilt checks ensure the right supplies are dispensed for both blinded and open-label studies;
Even if the internet connection is unavailable during time-critical patient consultations, the system works offline and has the backup of a 24/7 call center to enable data capture and dispensation to proceed with minimal delay and smooth recovery;
Emergency functions, like subject treatment unblinding, remain instantly accessible via endpoint IRT while being safely discrete and secure from the blinded eSource system;
At the end of the trial, monitors ensure compliance by reconciling returns and destructions, simply and easily, all within the same system.

As the complexities of clinical trials steadily increase, endpoint and Cmed are dedicated to enhancing their technologies further to minimize the burden on site staff and provide them with an optimal “consumer-like” experience.

About Cmed and encapsia

encapsia is an innovative, powerful, next-generation clinical data suite that delivers a complete solution to gather and manage data in clinical trials and apply live insights and analytics on trial progress to inform and support management decisions. www.encapsia.com encapsia is developed by the technology division of Cmed Group, with headquarters in Horsham, U.K. plus offices in Durham, North Carolina, Cambridge, Massachusetts, San Bruno, California and Timisoara, Romania. www.cmedresearch.com.

About endpoint

endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. For the past decade, their customer-obsessed team of professionals has been continuously evolving their suite of technologies to help Sponsors achieve clinical trial success. Their dynamic IRT solution, PULSE ®, for patient randomization and management, site management, and drug supply management and leading-edge clinical supplies management tool, DRIVE, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. endpoint is headquartered in San Francisco, California, with offices across the U.S., EU, and Asia. www.endpointclinical.com

SOURCE: endpoint Clinical

ReleaseID: 549349

NEW YORK, NY / ACCESSWIRE / June 20, 2019 / Reonomy (“the Company”), a leading provider of commercial real estate software and data solutions, today announced a new strategic relationship with CoreLogic – the leading provider of consumer, financial and property data, analytics and services. Through this agreement, Reonomy will be CoreLogic’s preferred commercial real estate data partner and will continue to leverage CoreLogic’s best-in-class data trove of property information, further expanding the quantity and quality of Reonomy’s coverage.

Since early 2018, CoreLogic has been an integral part of Reonomy’s robust data sourcing strategy. Reonomy’s proprietary data is collected from a variety of public and exclusive private data sources, with CoreLogic being a primary provider of property and transactional information. Now, CoreLogic will join Reonomy’s diverse partner network as a preferred provider.

“Expanding our relationship with CoreLogic really reinforces the quality of our property data as we continue to grow and scale,” said Rich Sarkis, chief executive officer at Reonomy. “This collaboration has enhanced our data accuracy on all levels – there aren’t many other businesses in our space that can say they’ve secured this type of market-leading position, and I think it really separates us from the noise.”

As the industry’s largest database of commercial property information, Reonomy is best known for its user-friendly prospecting web application. Now, the Company is making strides to solve data enablement and aggregation challenges for the market’s largest enterprise players through its technology and machine learning – the same solutions that have built Reonomy’s successful prospecting tool. By stitching and integrating transactional, physical and owner data, these technologies allow companies to build their source of truth by making their internal commercial real estate data comprehensive and scalable.

With CoreLogic, Reonomy expands its expansive data network. This diverse ecosystem of the industry’s top data and commercial real estate companies secures the most comprehensive aggregation of commercial real estate data. Through these partnerships, Reonomy customers can bring their business into a new age of data connection, with access to accurate and updated ownership, sales, debt and tax records for over 50 million properties across the United States.

“Reonomy is transforming the way commercial real estate businesses think about their data strategy,” said Shaleen Khatod, executive general manager of CoreLogic’s Data & Advisory Solutions. “When it comes to real estate, we recognize that the commercial industry needs a better way to connect their world. We’re excited to team up with Reonomy to offer best-in-class solutions for the commercial space.”

About Reonomy:

Reonomy leverages big data, partnerships and machine learning to connect the fragmented, disparate world of commercial real estate. By creating a single source of truth, Reonomy products empower individuals, teams and companies to share information, unlock insights and discover new opportunities. For more information, please visit www.reonomy.com.

About CoreLogic:

CoreLogic, the leading provider of property insights and solutions, promotes a healthy housing market and thriving communities. Through its enhanced property data solutions, services and technologies, CoreLogic enables realtors, financial institutions, insurance carriers, government agencies and other housing market participants to help millions of people find, acquire and protect their homes. For more information, please visit www.corelogic.com.

Media Contact:

Champaign Williams
Champaign.Williams@antennagroup.com

SOURCE: Reonomy

ReleaseID: 549348

PHOENIX, AZ / ACCESSWIRE / June 20, 2019 / GO Car Wash, the nation’s newest express car wash platform, has acquired Big Splash Car Wash, with five locations in the Kansas City area.

Established in 2010, Big Splash has grown to have operations in Kansas City; Overland Park, KS; and Grandview; Kansas City, MO.

“We are very pleased to add Big Splash to our GO Car Wash team in the Kansas City area,” said Darren Skarecky, CEO of GO Car Wash. “Jason and Claire Cunningham have established a solid business with an excellent team and a loyal customer base. We will continue to deliver high-quality service to customers throughout the Kansas City area.”

“When JT Thomson from GO Car Wash first approached us, it was an extremely smooth process,” said Jason Cunningham, Big Splash co-owner. “Claire and I spent the past decade building our Kansas City-area business, and we are excited to see the next chapter of our washes operating under the GO Car Wash umbrella.”

This acquisition represents the second in the Kansas City area in the last two months. GO Car Wash acquired two Travel Clean Express Car Wash locations in May 2019. The completion of these two acquisitions brings GO Car Wash to seven locations in the Kansas City area and on-track to reach its goal of operating 20-plus locations throughout the market.

“We are aggressively looking for other opportunities to continue to build out our presence in the Kansas City market and are excited about the other opportunities in the pipeline,” said JT Thomson, chief operating officer at GO Car Wash.

GO Car Wash is looking to hire more teammates as they create the most customer-centric car wash in the Kansas City area.

“As we continue to grow, we are adding to the GO Car Wash team, so we’re targeting high energy, customer-facing employees who are excited to join a bigger company with a strong career path for them,” Thomson said.

GO Car Wash will continue to deploy a multi-pronged growth strategy focused on acquisitions, partnerships and new site build outs.

Media Contacts

GO Car Wash
Darren Skarecky
President and CEO
Darren.Skarecky@GOCarWash.com
480-744-0154

JT Thomson
Chief Operating Officer
JT.Thomson@GOCarWash.com
480-744-0495

About Us

About Go Car Wash

GO Car Wash was founded in 2019 with the goal of building a multi-regional car wash company with clusters throughout secondary cities across North America. Headquartered in Phoenix, GO Car Wash plans to focus primarily on high-quality exterior express car washes, with a multi-pronged growth strategy focused on acquisitions, partnerships and new site build outs.

Links

www.gocarwash.com

SOURCE: GO Car Wash

ReleaseID: 549347

Significant reduction of levodopa-induced dyskinesia by AV-101 observed in “gold standard” MPTP non-human primate model of Parkinson’s disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company committed to developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced positive results of recent preclinical studies of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a widely-used MPTP non-human primate model for reproducing motor complications of Parkinson’s disease (PD), including dyskinesia (sudden uncontrolled movements) observed in PD patients treated with levodopa. In the MPTP primate model, AV-101’s antidyskinetic effects were similar to those generally observed with amantadine therapy, but AV-101 did not cause adverse effects experienced with amantadine.

The MPTP primate model used in this study is the “gold standard” for animal modeling of PD and has been used extensively to study both antiparkinsonian therapies and levodopa-induced dyskinesia (LID). MPTP is a neurotoxin that kills dopaminergic neurons in the striatum, producing motor symptoms similar to those of PD. In this study, AV-101’s efficacy against LID was measured through behavioral scores on a dyskinesia scale, and a Parkinsonian disability scale was used to measure levodopa antiparkinsonian efficacy. This study demonstrated that AV-101 significantly (p = 0.01) reduced LID without affecting the timing, extent, or duration of the therapeutic benefits of levodopa. This new preclinical study was conducted by Dr. Thérèse Di Paolo, Professor in the Faculty of Pharmacy at Laval University and among the world’s leading researchers focused on Parkinson’s disease and LID, pursuant to VistaGen’s research agreement with CHU de Québec – Université Laval Research Center in Québec, Canada. Summary results of the study will be presented at an upcoming scientific conference.

“The antidyskinetic activity of AV-101 that we measured compares favorably with our observation with amantadine in parkinsonian monkeys,” said Dr. Di Paolo. “Better than amantadine, with its known side effects (in humans with Parkinson’s disease and in parkinsonian monkeys), we observed no adverse effects with AV-101.”

A pivotal pathological hallmark of PD is a loss of dopamine neurons in the substantia nigra. Loss of dopamine neurons is thought to be due to neurotoxicity associated with misfolding of proteins and is associated with increased signaling of glutamate, the most abundant excitatory neurotransmitter in the brain. Increased glutamate activity is involved with aberrant neuronal signaling and excitotoxic death of neurons.

“The NMDA receptor plays a major role in glutamatergic signaling and has been shown to be a therapeutic target for LID,” said H. Ralph Snodgrass, Ph.D., VistaGen’s Chief Scientific Officer. “AV-101’s active metabolite, 7-Cl-KYNA, is a potent and selective NMDA receptor glycine site antagonist with neuroprotective properties. These recent results confirm our prior antidyskinesia study in this MPTP monkey model. We believe these preclinical data and AV-101’s positive safety profile in all clinical studies to date support AV-101’s potential to treat LID, while both maintaining the antiparkinsonian benefits of levodopa and without causing hallucinations or other serious side effects that may be associated with current amantadine-based therapy for LID,” added Dr. Snodgrass.

About Parkinson’s Disease

PD is the second most common neurodegenerative disease worldwide, affecting approximately one million people in the U.S. and ten million people worldwide, according to the Parkinson’s Foundation. Although there is no “one-size-fits-all” description of PD, PD is a complex neurodegenerative disorder that occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, resulting in progressive deterioration of voluntary motor control. Classic PD motor symptoms include muscular rigidity, resting tremor, and postural and gait impairment. Typically, PD patients present with a combination of motor and non-motor symptoms. Non-motor symptoms may include cognitive impairment, sleep disorders, pain and fatigue. There is currently no medication to slow, delay, stop or cure PD, and currently available treatments are symptomatic. Treatment of motor symptoms with oral levodopa, introduced about 50 years ago, remains the gold standard treatment.

About Levodopa-Induced Dyskinesia

LID is a disorder that affects people with PD who are treated with the current standard of care, oral levodopa, for an extended period of time. Oral levodopa remains the most effective therapy for motor symptoms of PD. However, after continuous long-term use (longer than five years), many PD patients experience LID. Although clinical manifestations of LID are heterogenous, LID is commonly associated with abnormal involuntary movements, including chorea and dystonia. These motor complications tend to become more severe as PD progresses and as the duration of levodopa treatment is extended, until the impact of LID may compromise the advantage of treatment with levodopa. PD treatment with levodopa is routinely delayed due to concerns over LID. Once LID develops, levodopa-treated PD patients may be faced with a choice between immobility due to untreated and uncontrolled PD, or mobility with the associated LID.

About AV-101

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including chronic neuropathic pain, epilepsy, major depressive disorder, LID and many others. AV-101 is an oral prodrug of 7-Cl-KYNA which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new at-home treatment for multiple CNS indications with high unmet need. The FDA has granted Fast Track designation for development of AV-101 as both a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company committed to developing new generation medicines for CNS diseases and disorders with high unmet need. VistaGen’s pipeline includes three clinical-stage CNS drug candidates, AV-101, PH10 and PH94B. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This release contains various statements concerning VistaGen’s future expectations, plans and prospects, including without limitation, our expectations regarding development and commercialization of our drug candidates, including AV-101 for treatment of LID in patients with PD receiving levodopa therapy, all of which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and may cause actual results to differ materially from those contemplated in these forward-looking statements. Among these risks is the possibility that (i) we may encounter unexpected adverse events in patients during our clinical development of any product candidate, including AV-101, that cause us to discontinue further development, (ii) we may not be able to successfully demonstrate the safety and efficacy of AV-101 or any of our other product candidates at each stage of clinical development, (iii) success in preclinical studies or in early-stage clinical trials may not be repeated or observed in ongoing or future studies, and ongoing or future preclinical and clinical results may not support further development of, or be sufficient to gain regulatory approval to market our drug candidates, including AV-101, (iv) decisions or actions of regulatory agencies may negatively affect the progress of, and our ability to proceed with, further clinical studies or to obtain marketing approval for our drug candidates, (v) we may not be able to obtain or maintain adequate intellectual property protection and other forms of marketing and data exclusivity for our product candidates, (vi) we may not have access to or be able to secure substantial additional capital to support our operations, including our ongoing clinical development activities, and (vii) we may encounter technical and other unexpected hurdles in the manufacturing and development of any of our product candidates. Certain other risks are more fully discussed in the section entitled “Risk Factors” in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC’s website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact

Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com

SOURCE: VistaGen Therapeutics, Inc.

ReleaseID: 549343